Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | XDH | P47989 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5418162 | 0.85 | SMN1; SMN2 (0.58) | LMNAXDHALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL5322818 | 0.82 | XDH (0.52) | XDHALDH1A1SMN1; SMN2MAPTPLA2G2A | |
| SCHEMBL5462266 | 0.82 | TP53 (0.58) | LMNAXDHALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL1780399 | 0.80 | ALDH1A1 (0.64) | LMNAXDHALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL5462258 | 0.79 | ALDH1A1 (0.63) | LMNAALDH1A1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL5326339 | 0.79 | XDH (0.46) | XDHALDH1A1SMN1; SMN2TP53MAPT | |
| SCHEMBL5461187 | 0.78 | DRD2 (0.45) | LMNAXDHALDH1A1MAPTKDM4E | |
| SCHEMBL12628344 | 0.76 | KCNA3 (0.48) | LMNAXDHALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL12628346 | 0.76 | BCHE (0.56) | LMNAALDH1A1SMN1; SMN2ACHEKCNA3 | |
| SCHEMBL5323650 | 0.76 | ABCC2 (0.49) | XDHALDH1A1PLA2G2AKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070287699-A1 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070287699-A1 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070287699-A1 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| WO-2007130499-A2 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287699-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | LMNA 4460/4885XDH 693/4885ALDH1A1 1759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.